People: IGI Laboratories Inc (IG)

IG on American Stock Exchange

5.42USD
23 Jul 2014
Price Change (% chg)

$-0.03 (-0.55%)
Prev Close
$5.45
Open
$5.48
Day's High
$5.50
Day's Low
$5.32
Volume
191,573
Avg. Vol
339,275
52-wk High
$6.14
52-wk Low
$1.43

Search Stocks

Summary

Name Age Since Current Position

Jason Grenfell-Gardner

38 2012 President, Chief Executive Officer, Director

Jenniffer Collins

44 2011 Chief Financial Officer

Damian Finio

2014 Director

Narendra Borkar

72 2009 Independent Director

Bhaskar Chaudhuri

1 2010 Independent Director

James Gale

62 2009 Independent Director

Biographies

Name Description

Jason Grenfell-Gardner

Mr. Jason Grenfell-Gardner is President, Chief Executive Officer, Director of IGI Laboratories, Inc. Since July 2008, Mr. Grenfell-Gardner, was the Senior Vice President of Sales and Marketing for West-Ward Pharmaceuticals Corp., the U.S. Subsidiary of Hikma Pharmaceuticals PLC, a generic pharmaceutical manufacturer. Prior to that, Mr. Grenfell-Gardner served as West-Ward Pharmaceuticals’s General Manager - Injectables, North America (December 2007 to July 2008) and its Director of Business Development (October 2006 to December 2007). Mr. Grenfell-Gardner joined West-Ward Pharmaceuticals in 2004 to lead its initial public offering. Prior to joining West-Ward Pharmaceuticals, Mr. Grenfell-Gardner was an investment banker with Trigon Capital. Prior to 2004, Jason gained a number of years of investment banking experience in Central and Eastern Europe with Trigon Capital, and served as Chairman of the Board of Sanitas Pharmaceuticals. Jason has an MA in Economics from the University of St. Andrews in Scotland, and an MBA from INSEAD, where he studied in both France and Singapore.

Jenniffer Collins

Ms. Jenniffer Collins is Chief Financial Officer of IGI Laboratories Inc., since July 21, 2011. Ms. Collins has twenty years of experience in accounting and finance. Prior to joining IGI, she most recently served from October 2006 to July 2011 as Vice President-Treasurer and previously the Corporate Controller at the Lightstone Group, a privately held real estate firm and The Lightstone Value Plus REIT, a publicly traded real estate investment trust. From January 2004 through October 2006, Ms. Collins also served as Corporate Controller for Orchid Cellmark, Inc., a publicly held biotechnology company, and from July 2001 through January 2004 Ms. Collins served as Director of Finance and Investor Relations for Tellium, Inc. a publicly held optical switching company, which was purchased by Zhone Technologies, Inc in November 2003. Her background also includes seven years of public accounting experience, including Pricewaterhouse Coopers. Jenniffer earned her CPA in New Jersey in 1993 and graduated with a B.S. in accounting from Lehigh University.

Damian Finio

Mr. Finio is currently President of Mountain Run Advisors LLC., a niche financial consulting firm. Prior to this role, Mr. Finio was VP & Chief Financial Officer of West-Ward Pharmaceuticals. West-Ward is a $500million generic pharmaceutical manufacturer based in New Jersey owned by HIKMA Pharmaceuticals. HIKMA is a $1.0 billion global pharmaceutical manufacturer headquartered in Amman, Jordan, and traded on the London Stock Exchange. Before joining West-Ward, Mr. Finio was VP, Finance, at Daiichi Sankyo Pharma Development, a large Japanese pharmaceutical company, where he managed both Finance and Outsourcing, and chaired the organization’s Global R&D Finance Committee. Prior to Daiichi Sankyo, he worked at AstraZeneca for nearly 14 years in a variety of financial roles with increasing responsibility, the last of which was Senior Director, Managed Markets Finance. He began his career in public accounting with KPMG, holds a B.S. in Accounting from The Pennsylvania State University and an MBA from The University of Delaware. He is also a Certified Public Accountant and Certified Treasury Professional. He is Director of the Company.

Narendra Borkar

Mr. Narendra N. Borkar is Independent Director of IGI Laboratories, Inc., since September 2009. Mr. Borkar has served as Chief Executive Officer of Aurobindo Pharma USA (2004-2006), Chief Executive Officer of Caraco Pharmaceutical Laboratories (1997- 2003), various senior roles for Novartis (formerly Ciba-Geigy) (1981-1997), General Manager of Apte Amalgamation (1979-1981), Works Engineer for Hoffman La Roche (1976-1979), Project Manager for Union Carbide Corp. and Merck & Company, Inc. (1966-1976).

Bhaskar Chaudhuri

Dr. Bhaskar Chaudhuri, Ph.D., is Independent Director of IGI Laboratories, Inc., since December 2010. Mr. Chaudhuri has more than 20 years experience in pharmaceutical management, research and development. Mr. Chaudhuri served as President of Valeant Pharmaceuticals International until September 2010. Prior to joining Valeant, upon Valeant’s acquisition of Dow Pharmaceutical Sciences, Inc. in 2008, Mr. Chaudhuri served for seven years as Dow’s President and Chief Executive Officer and a member of Dow’s Board of Directors from 2003 to 2008. Prior to that, Mr. Chaudhuri served as Executive Vice President of Scientific Affairs at Bertek Pharmaceuticals, a subsidiary of Mylan Laboratories. Prior to his positions at Bertek, Mr. Chaudhuri served as the General Manager of the Dermatology Division of Mylan Laboratories. Mr. Chaudhuri joined Mylan through the acquisition of Penederm, Inc., where he worked from 1992 to 1998 in a number of senior positions before becoming the Vice President of R&D. Mr. Chaudhuri holds a Doctorate in Physical Pharmacy from the University of Louisiana, a Masters of Science in Industrial Pharmacy and a Bachelors of Science in Pharmacy from India.

James Gale

Mr. James C. Gale is Independent Director of IGI Laboratories Inc., since May 2009. He is Founding Partner of Signet Healthcare Partners. Prior to founding Signet, Mr. Gale was head of principal investment activities and investment banking at Gruntal & Co., LLC. Prior to joining Gruntal, Mr. Gale originated and managed private equity investments for Home Insurance Co., Gruntal’s parent. Earlier in his career, Mr. Gale was a senior Investment Banker at E.F. Hutton & Co. Mr. Gale is currently the Chairman of the Board of Alpex Pharma S.A. and also serves on the Board of Directors of Anteis SA, Octoplus BV, Pfenex Inc., Spepharm BV and Paladin Laboratories. Mr. Gale holds a Masters of Business Administration from the University of Chicago.

Basic Compensation

Name Fiscal Year Total

Jason Grenfell-Gardner

1,522,290

Jenniffer Collins

287,433

Damian Finio

--

Narendra Borkar

--

Bhaskar Chaudhuri

--

James Gale

--
As Of 30 Dec 2013

Options Compensation

Search Stocks